Back to top
more

Hologic (HOLX)

(Real Time Quote from BATS)

$79.43 USD

79.43
506,493

-1.06 (-1.32%)

Updated Nov 7, 2024 01:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

GE HealthCare (GEHC) Q2 Earnings Beat Estimates, Net Margin Up

by Zacks Equity Research

GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.

DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.

Brokers Suggest Investing in Hologic (HOLX): Read This Before Placing a Bet

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Hologic (HOLX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up

by Zacks Equity Research

Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company???s transformational plans continue to benefit its operating income.

Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across the majority of its segments drives its second-quarter sales amid business challenges.

Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Hologic (HOLX) delivers strong performances across all its franchises in the third quarter of fiscal 2024.

Compared to Estimates, Hologic (HOLX) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Hologic (HOLX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 3.92% and 1.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised

by Zacks Equity Research

Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.

HOLX or SONVY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. SONVY: Which Stock Is the Better Value Option?

Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

by Zacks Equity Research

Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.

Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions

by Zacks Equity Research

Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.

Alphatec's (ATEC) New EOS Insight System to Boost Spine Care

by Zacks Equity Research

Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.

Gear Up for Hologic (HOLX) Q3 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Hologic (HOLX) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

PacBio's (PACB) Revio System to Boost Novogene's German Lab

by Zacks Equity Research

PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.

Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now

by Zacks Equity Research

QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.

Hologic (HOLX) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

In the latest trading session, Hologic (HOLX) closed at $78.38, marking a +0.35% move from the previous day.

Boston Scientific (BSX) Banks on Global Expansion, Innovation

by Zacks Equity Research

In EMEA, Boston Scientific (BSX) is successfully expanding its base, banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand.

Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

GE HealthCare (GEHC) New Deal to Aid Its Ultrasound Portfolio

by Zacks Equity Research

GE HealthCare (GEHC) announces that it has entered into an agreement to acquire Intelligent Ultrasound's AI software business to strengthen its ultrasound portfolio.

Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.